Hazards of non-practolol beta-blockers.

Antinuclear antibodies in patients receiving non-practolol beta-blockers.

Antinuclear antibodies (ANA) were found in 54 (7.0%) out of 767 treated hypertensive patients compared with 59 (2.4%) out of 2470 healthy controls. Inclusion of a non-practolol beta-blocker in the treatment regimen did not significantly affect the incidence of ANA. ANA was found in significantly more patients being treated with methyldopa (13.0%) than patients receiving other hypotensive agents...

Beta-blockers.

Beta blockers in non-cardiac surgery: haemodynamic data needed.

1930 www.thelancet.com Vol 372 December 6, 2008 or febuxostat). Enhanced understanding of pathophysiological mechanisms might lead to improved drugs, with reduced potential for side-eff ects compared with today’s uricosurics. Even more exciting is the idea that responding to the defects of these transporter proteins might have further benefi cial eff ects, because they could also transport othe...

Beta-adrenergic blockers.

beta-Adrenergic blocking drugs have been available for several years to treat ischemic heart disease and other cardiovascular and noncardiovascular disorders. There are multiple drugs in this class with various pharmacodynamic and pharmacokinetic properties that may be important in specific clinical situations and in avoiding certain adverse reactions. These drugs have been shown to be efficaci...

Beta-blockers for hypertension

BACKGROUND Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line therapy for hypertension. Howev...